SNV4818 in Participants with Advanced Solid Tumors

Description

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

Conditions

Advanced Solid Tumors

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 As Monotherapy or in Combination with Other Anticancer Agents in Participants with Advanced Solid Tumors

SNV4818 in Participants with Advanced Solid Tumors

Condition
Advanced Solid Tumors
Intervention / Treatment

-

Contacts and Locations

Houston

The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Advanced or metastatic solid tumor with an activating PIK3CA mutation.
  • * Refractory to or intolerant of available therapies
  • * Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in blood.
  • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • * Diagnosis of a primary CNS malignancy
  • * Active brain metastases or carcinomatous meningitis
  • * Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
  • * Inadequate organ function
  • * Clinically significant ECG abnormalities, including QTcF ≥ 470 ms

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Synnovation Therapeutics, Inc.,

Study Record Dates

2026-12